Comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes.
Immunai’s end-to-end single-cell platform enables high resolution profiling of the immune system at industrial scale, generating biological insights that accelerate R&D and power novel discoveries.
We are a multidisciplinary team of biologists, computer scientists, engineers, mathematicians and operators singularly focused on solving an audacious challenge. We take an engineering-first approach to biology.
Data Driven: Immunai Adds Biocuration, European Hubs with Nebion Acquisition
Immunai Acquires Dropprint Genomics and Strengthens Leadership Team with Experts in Immunology to Expand Target Discovery Capabilities
Immunai raises $60M as it expands from improving immune therapies to discovering new ones, too
We are excited to explore strategic partnerships with academic research institutions, biopharmaceutical companies, and biotechs. to expand the use of our technology and data platform to unlock biological insights, advance novel therapeutic discovery, and accelerate R&D.Contact Us